Altria Group, INC.: directors' dealings · United States · SEC (Form 4)

About Altria Group, INC.

Altria Group, Inc. is a U.S.-listed company traded on the NYSE under the ticker MO, headquartered in Richmond, Virginia, United States. The company traces its heritage back to Philip Morris & Co. and was renamed Altria Group in 2003, after which it underwent a series of portfolio shifts and divestitures that left it focused on the domestic nicotine market. While the modern business is narrower than its former conglomerate structure, Altria remains one of the most recognizable names in U.S. tobacco, with deep roots in manufacturing, distribution, and brand building. ([altria.com](https://www.altria.com/en/about-altria/our-heritage?utm_source=openai)) Altria’s current operations are centered on two reportable segments: smokeable products and oral tobacco products. In smokeables, the company’s flagship franchise is Marlboro through Philip Morris USA, supplemented by brands such as Black & Mild and other niche cigarette and cigar offerings. In oral tobacco, Altria holds leading positions with Copenhagen and Skoal, and also markets on!, its oral nicotine pouch brand. Beyond these legacy categories, Altria has been building a smoke-free portfolio through assets such as NJOY, its e-vapor platform, and Horizon Innovations, a joint venture with JT Group for the U.S. commercialization of heated tobacco stick products. The strategic message is clear: preserve cash from combustible products while trying to grow or at least establish relevance in reduced-risk nicotine formats. ([altria.com](https://www.altria.com/about-altria/at_a_glance/corporate-fact-sheet?utm_source=openai)) From a competitive standpoint, Altria retains a strong U.S. market position thanks to iconic brands, a powerful distribution footprint, established retail relationships, and significant regulatory experience. Those strengths help support margins and cash generation, which has historically underpinned the company’s dividend appeal. However, the industry backdrop remains challenging: cigarette volumes continue to trend down structurally, the regulatory burden is heavy, illicit products are a recurring issue, and the transition toward smoke-free alternatives is still uneven. In other words, Altria combines a highly cash-generative incumbent franchise with a long-term secular decline in its core category. ([altria.com](https://www.altria.com/?utm_source=openai)) Recent developments underscore both resilience and execution risk. In the first quarter of 2025, Altria reported results ahead of market expectations and reaffirmed full-year guidance, even as cigarette volumes fell sharply and the company recorded a large impairment tied to NJOY following a patent dispute. The company also noted that, effective March 31, 2025, NJOY ACE devices and pods were prohibited from being imported, marketed, sold, and distributed in the United States due to an International Trade Commission order. For investors in France, Belgium, and Switzerland, MO is best viewed as a mature U.S. defensive equity: attractive for income and brand strength, but exposed to secular volume pressure and still dependent on successful smoke-free execution. ([businesswire.com](https://www.businesswire.com/news/home/20250427178410/en/Altria-Reports-2025-First-Quarter-Results-Reaffirms-Full-Year-Guidance?utm_source=openai))